Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Dermatologic 3Plasma cell 2Myeloid 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Amplified Fragment Length Polymorphism Analysis × Genitourinary × Clear all
NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
73 enrolled 16 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Completed
47 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00717587 2014-01-10

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡